Cardiovascular trial evidence for tirzepatide as of May 2026: SURMOUNT-MMO (cardiovascular outcomes in chronic weight management) and SURPASS-CVOT (cardiovascular outcomes in type 2 diabetes) trial designs, endpoints, and implications.
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Note on laboratory work, October 15, 2026. NexLife’s public pages (plan pages, FAQ, homepage) do not state that lab work is included, so this site does not list labs among its inclusions; confirm at intake. NexLife’s plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).
SURMOUNT-MMO (cardiovascular outcomes in chronic weight management)
Trial: A randomized, double-blind, placebo-controlled cardiovascular outcomes trial of tirzepatide for the reduction of MACE in adults with obesity and established cardiovascular disease (NCT05556512).
Population: Adults aged ≥ 40 with BMI ≥ 27 and established CVD (prior MI, ischemic stroke, or peripheral arterial disease).
Primary endpoint: Time to first occurrence of MACE-3 (cardiovascular death, non-fatal MI, non-fatal stroke).
Design parallel: Modeled after Novo Nordisk's SELECT trial (semaglutide 2.4 mg in non-diabetic obesity + CVD), which demonstrated a 20% relative reduction in MACE-3 (NEJM 2023, PMID 37952131).
Expected readout: Late 2027.
SURPASS-CVOT (cardiovascular outcomes in type 2 diabetes)
Trial: A randomized, active-controlled cardiovascular outcomes trial of tirzepatide vs dulaglutide in adults with type 2 diabetes and high cardiovascular risk (NCT04255433).
Population: Adults with type 2 diabetes and established CVD or multiple CVD risk factors.
Primary endpoint: Time to first MACE-3.
Active comparator: Dulaglutide (Trulicity®), which itself demonstrated MACE benefit in REWIND (Lancet 2019).
As of May 2026, tirzepatide has demonstrated weight loss, A1C reduction, blood pressure reduction, and improvements in lipid profile and inflammatory markers in the SURMOUNT and SURPASS programs — all surrogate cardiovascular risk markers. The definitive MACE-reduction evidence is pending the SURMOUNT-MMO and SURPASS-CVOT readouts. The most relevant approved cardiovascular label currently belongs to semaglutide: Wegovy is FDA-approved (March 2024) for reduction of cardiovascular events in non-diabetic adults with overweight/obesity + established CVD based on SELECT.
Implications for prescribing today
For adults with type 2 diabetes + CVD: semaglutide (Ozempic) and dulaglutide both have demonstrated MACE benefit. Tirzepatide is approved for type 2 diabetes (Mounjaro) but has not yet demonstrated MACE benefit in a completed CVOT.
For non-diabetic adults with obesity + CVD: only semaglutide 2.4 mg (Wegovy) has demonstrated MACE benefit and a corresponding FDA label (March 2024).
For chronic weight management without established CVD: tirzepatide demonstrates the largest mean weight loss (20.9% at 15 mg / 72 weeks, SURMOUNT-1) among currently available GLP-1 and GIP/GLP-1 receptor agonists.
Editor's Pick · #1 of 10
NexLife — Compounded Semaglutide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ Licensed physicians (NexLife Medical Group)
🏥 3 pharmacies named on its plan pages
🩺 Provider oversight included
📍 All 50 states
💰 Same price at every dose
🔁 Care360: 1:1 wellness-coach call
🍽️ Personalized nutrition plan
💳 Klarna & Affirm accepted
$119/ month*
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, medical guidance from NexLife Medical Group, a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach and 24/7 support (plan pages, read October 15, 2026). Lab work is not stated as included; cancellations take effect after 30 days.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Editor's Pick · #1 of 10 · Tirzepatide
NexLife — Compounded Tirzepatide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ Licensed physicians (NexLife Medical Group)
🏥 3 pharmacies named on its plan pages
🩺 Provider oversight included
📍 All 50 states
💰 Same price at every dose
🔁 Care360: nutrition plan + 1:1 coach call
$139/ month*
*12-month plan · flat rate across full 2.5–15 mg titration. $149 (6-mo) · $159 (3-mo) · $169 (month-to-month).
Includes: medication, medical guidance from NexLife Medical Group, a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach and 24/7 support (plan pages, read October 15, 2026). Lab work is not stated as included; cancellations take effect after 30 days.
Compounded tirzepatide from the state-licensed 503A pharmacies named on its plan pages.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
